[1] Hosaka T,Nakamagoe K,Tamaoka A,et al.Hemolytic uremic syndrome-associated encephalopathy successfully treated with corticosteroids[J].Intern Med,2017,56(21):2937-2941.
[2] 殷培,李冀军,宋岩,等.尿毒症老年血液透析患者死亡相关因素分析[J].贵州医科大学学报,2017,42(4):482-485.
[3] Sperati CJ,Moliterno AR.Thrombotic microangiopathy: focus on atypical hemolytic uremic syndrome[J].Hematol Oncol Clin North Am, 2015,29(3):541-559.
[4] 方峻,夏凌辉,魏文宁,等.尿毒症患者凝血因子Ⅶ水平及其影响因素[J].中国实验血液学杂志,2004,12(6):730-732.
[5] Contaifer D Jr,Carl DE,Warncke UO,et al.Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients[J].J Lipid Res,2017,58(3):586-599.
[6] Wu VC,Huang TM,Shiao CC,et al.The hemodynamic effects during sustained low-efficiency dialysis versus continuous veno-venoushemofiltration for uremic patients with brain hemorrhage: a crossover study [J].J Neurosurg, 2013,119(5):1288-1295.
[7] 张彦峰,罗伟雄,罗伟文.连续性静脉-静脉血液滤过联合血液灌流对严重脓毒症患者凝血功能的影响[J].广东医学,2016,37(13):1987-1989.
[8] Laurence J,Haller H,Mannucci PM,et al.Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis[J].Clin Adv Hematol Oncol,2016,11(11):2-15.
[9] 王伟, 张国召, 任稹,等. 尿毒症患者死亡危险因素分析[J]. 现代仪器与医疗, 2017, 23(4):58-59.
[10] Roumenina LT,Rayes J,Frimat M,et al.Endothelial cells:source,barrier,and target of defensivemediators[J].Immunol Rev,2016,274(1):307-329.
[11] Wong LS,Wu T,Lee CH.Inflammatory and noninflammatory itch: implications in pathophysiology-directed treatments[J].Int J Mol Sci,2017,18(7): E1485.
[12] Niwa N.Renal hemorrhage caused by acquired inhibitors tocoagulationfactors VIII and V in ahemodialysis patient [J].CEN Case Rep,2016,5(2):223-226.
[13] 贾军利,王淑萍,李迎婕,等.血液透析联合血液灌流对维持性血液透析患者微炎症状态及骨代谢影响 [J].临床军医杂志,2017,17(12):1282-1284.
[14] 蒋玲,安仲武,秦继宝,等.维持性血液透析患者血浆D-二聚体及纤溶系统变化研究[J].检验医学与临床,2015,11(5):621-625. |
2018, Vol. 35 
